Scaffolding Supports the Hippo
- PMID: 38848765
- PMCID: PMC11452332
- DOI: 10.1016/j.jcmgh.2024.05.011
Scaffolding Supports the Hippo
Comment on
- doi: 10.1016/j.jcmgh.2024.04.005
Similar articles
-
A connection between phosphatidylinositol 5-phosphate and the Hippo pathway to prevent epithelial-mesenchymal transition in cancer.Sci Signal. 2024 May 28;17(838):eadp3504. doi: 10.1126/scisignal.adp3504. Epub 2024 May 28. Sci Signal. 2024. PMID: 38805585 Review.
-
Hippo signaling at a glance.J Cell Sci. 2010 Dec 1;123(Pt 23):4001-6. doi: 10.1242/jcs.069070. J Cell Sci. 2010. PMID: 21084559 Free PMC article. No abstract available.
-
Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.Cancer Lett. 2021 Jun 1;507:112-123. doi: 10.1016/j.canlet.2021.03.006. Epub 2021 Mar 15. Cancer Lett. 2021. PMID: 33737002 Free PMC article. Review.
-
Tweaking synaptic plasticity: Deciphering the role of WWC1 in memory opens new therapeutic horizons.Sci Signal. 2024 Jun 25;17(842):eadp5354. doi: 10.1126/scisignal.adp5354. Epub 2024 Jun 25. Sci Signal. 2024. PMID: 38917220 Review.
-
Hippo gains weight: added insights and complexity to pathway control.Sci Signal. 2013 Oct 8;6(296):re7. doi: 10.1126/scisignal.2004208. Sci Signal. 2013. PMID: 24106343
References
-
- Pfeifer G.P., Dammann R., Tommasi S. RASSF proteins. Curr Biol. 2010;20:R344–R345. - PubMed
-
- Eckfeld K., Hesson L., Vos M.D., et al. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004;64:8688–8693. - PubMed
-
- De Smedt E., Maes K., Verhulst S., et al. Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression. Cancer Res. 2018;78:1155–1168. - PubMed
-
- Han Y., Dong Q., Hao J., et al. RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion. Tumour Biol. 2016;37:4865–4871. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources